key: cord-0995889-wtfafnj2
authors: Shipton, Michael J.; Kinsella, Paul M.; Davis, Thomas; Azzato, Francesca; Taiaroa, George; Szer, Jeff; Routledge, David; Smibert, Olivia
title: Infective hyperammonaemic encephalopathy after allogeneic stem cell transplant
date: 2022-04-11
journal: Bone Marrow Transplant
DOI: 10.1038/s41409-022-01669-8
sha: c0fa09cf91c9bfc33b365cb709d9083d842a3ffb
doc_id: 995889
cord_uid: wtfafnj2

nan

A non-contrast CT scan of her brain revealed no intracranial haemorrhage, cerebral oedema nor evidence of opportunistic infection. Bloods were notable for a remarkably elevated serum ammonia concentration of 946 µmol/L (normal < 60 µmol/L, Table 1 ).

Several differential diagnoses for hyperammonaemia were considered, including hepatic failure, urea cycle disorder (UCD), drug-induced, and Ureaplasma/Mycoplasma hominis infection. On discussion with the Metabolic Diseases Unit, a urease-producing bacteria was thought to be the most likely cause. Empiric treatment was initiated for Ureaplasma spp. and M. hominis with azithromycin 500 mg IV daily and ciprofloxacin 400 mg IV twice daily, pending further investigations. Hyperammonaemia was addressed with cessation of TPN and replacement with 10% dextrose IV, 10% Intralipid IV and sodium benzoate 12 g IV daily.

Haemodialysis was instituted owing to the risk of fatal cerebral oedema. A serum amino acid panel demonstrated low levels of citrulline, arginine and other amino acids, but a urine metabolic screen was non-diagnostic for UCD such as deficiency of carbamoylphosphate synthetase 1 or ornithine transcarbamylase.

Despite a reduction in the serum ammonia, there was no evidence of clinical improvement. In the absence of engraftment and in keeping with the patient's wishes she was transitioned to end-of-life care and died on day 27. Given the strong clinical suspicion of infection with a urease-producing organism, additional investigations were requested. Blind subculture of blood cultures to Ureaplasma spp./Mycoplasma media produced no growth. PCR on EDTA blood sample four days prior to death detected Ureaplasma parvum, and confirmed using a stored DNA extract from the preceding day. To further investigate this, novel primers and probes specific for Ureaplasma parvum were designed as described previously [2] . This assay was also positive on both samples, excluding non-specific amplification as a cause of the previous positive PCR. Ureaplasma parvum PCR of urine was also positive, suggesting a possible portal of entry. A posthumous liver biopsy (within ten hours of death) revealed zone three necrosis but no visualised organisms (on Gram and silver stains) nor eosinophilic inclusions on periodic acid Schiff stain, negative immunohistochemistry for EBV, CMV, HSV and hepatitis B, and negative trichome stain. Multiple microbiological tests on liver tissue were negative including bacterial and fungal culture, Ureaplasma/Mycoplasma culture and broad target PCR techniques (16 S ribosomal RNA for bacteria and internal transcribed spacer for fungi).

Ureaplasma spp, including U. parvum and U. urealyticum are commensal bacteria which commonly reside in the urogenital tract [3] . Ammonia is released during metabolism to generate ATP through urea hydrolysis by urease. Ureaplasma spp. lack a cell wall and therefore cannot be visualised by Gram stain; diagnosis is reliant on a high index of suspicion with subsequent inoculation of enriched media, or molecular methods such as PCR. Presentations in immunocompromised hosts are protean including disseminated infection with septic arthritis, endocarditis or central nervous system infection, and hyperammonaemia syndrome.

The clinical manifestations of hyperammonaemia are variable, ranging from irritability and headache to encephalopathy, seizures and coma, especially with ammonia levels >200 µmol/L. Optimal treatment entails removal of excess ammonia with urgent continuous renal replacement therapy, and enhanced endogenous elimination via administration of substrates such as L-arginine, L-citrulline and L-ornithine, which promote the urea cycle [4] . Sodium benzoate reduces ammonia production by preventing metabolism of glutamine and glycine. IV dextrose decreases protein catabolism through provision of calories. Cessation of offending agents, for example sodium valproate and calcineurin inhibitors, is warranted. Efforts to limit ammonia intake are beneficial, including reduction of dietary protein and restriction or modification of TPN.

Hyperammonaemia syndrome is a well-described complication of solid organ transplantation, particularly of the lung, and portends a poor prognosis [4] . The focus of infection may be either donor-derived [5] or via translocation of the host's endogenous flora, presumably in the setting of urinary catheterisation [6] . In the context of AlloHSCT, historical cohorts indicate an incidence of <1% of idiopathic hyperammonaemia occurring early post-transplant with a high mortality [7] . Hyperammonaemia syndrome associated with Ureaplasma spp. has been described post-AlloHSCT [8] and promptly following chimeric antigen receptor T-cell therapy in two patients who had received AlloHSCT within twelve months, potentially mimicking immune effector cellassociated neurotoxicity syndrome [9, 10] . While pre-emptive screening and empiric treatment of those colonised with Ureaplasma spp. and Mycoplasma spp. has been promoted [11] , the authors believe this approach would be of limited clinical benefit and may increase resistance rates given the low frequency of infection with these commensal organisms.

Most Ureaplasma species are susceptible to macrolides and fluoroquinolones [12] , but resistance to these agents has been described. Importantly, antibiotics which target the cell wall have no activity, including all beta-lactams, which remain the cornerstone of treatment for febrile neutropenia in haematology patients.

Despite antimicrobial prophylaxis, AlloHSCT recipients remain at high risk of opportunistic infection. Given the inability for Ureaplasma spp./M. hominis to be cultured conventionally, a high index of suspicion is required. In immunocompromised patients who develop features of encephalopathy, it is prudent to consider assessment of serum ammonia levels in addition to other appropriate investigations. Confirmation of hyperammonaemia should prompt further investigation for Ureaplasma spp./M. hominis concurrent with hyperammonaemia-directed management. Empiric administration of antibiotics with activity against these organisms should take into consideration local resistance profiles. Alanine transaminase (U 

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

PCR for the detection of pathogens in neonatal early onset sepsis

Colonization with genital mycoplasmas in women

Hyperammonemia post lung transplantation: a review

Disseminated Ureaplasma infection as a cause of fatal hyperammonemia in humans

Donor-derived mycoplasma hominis and an apparent cluster of M. hominis cases in solid organ transplant recipients

Idiopathic hyperammonemia: a frequently lethal complication of bone marrow transplantation

Successful resolution of hyperammonemia following hematopoietic cell transplantation with directed treatment of Ureaplasma parvum infection

Lethal hyperammonemia in a CAR-T cell recipient due to Ureaplasma pneumonia: a case report of a unique severe complication

Severe hyperammonemia in chimeric antigen receptor T cells recipient-unusual differential diagnosis of encephalopathy syndrome

Prophylactic ureaplasmadirected antimicrobials in lung donors can prevent fatal hyperammonemia

MJS, PMK and TD wrote the manuscript. FA and GT performed laboratory analysis. JS, DR and OS provided feedback on the report. All authors read and approved the final manuscript.

JS has received funding for consulting fees from Takeda and Alexion; has received honoraria from Takeda, Alexion and Pfizer; and is on an advisory board for Prevail Therapeutics and Novartis. DR has received honoraria from Amgen, BMS, Pfizer, Janssen and Sandoz; and financial support for attending meetings from Amgen and BMS. All others authors report no conflicts of interest. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest.

The patient's next of kin provided informed consent for the publication of this case presentation.

Correspondence and requests for materials should be addressed to Olivia Smibert.Reprints and permission information is available at http://www.nature.com/ reprintsPublisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.